TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
RegulatoryapprovedWeltruzaPositive
AI Analysis
Summary
Teva Pharmaceutical received FDA approval for Weltruza as a once-monthly long-acting injectable treatment for schizophrenia, representing a regulatory achievement for the company's antipsychotic portfolio.
Outcome Details
FDA approval for once-monthly long-acting injection (LAI) formulation
Importance:8/10
Sentiment:
0.85
FDA approvalschizophrenialong-acting injectionWeltruzaregulatory
Related Companies
Read the original article
Published by yahoo_finance on October 12, 2026 3:07 PM